Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Period	Debt/Equity
2015-12-31	0.08
2016-12-31	0.37
2017-12-31	-5.60
2018-12-31	-1.03
2019-12-31	0.10
2020-12-31	0.24
2021-12-31	43.91
2022-12-31	-1.58
2023-12-31	-1.43
2024-12-31	-1.15

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GALT	$2.23	+1.60%	0.44M
3
4
5

Galectin Therapeutics Inc. (GALT) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Galectin Therapeutics Inc. Data in Excel

More GALT Financial Data